

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

4

FEE TRANSMITTAL
for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT \$180.00

Complete if Known

Application Number	09/882186
Filing Date	06/15/2001
First Named Inventor	Khanna et. al.
Examiner Name	Unknown
Group Art Unit	Unknown
Attorney Docket No.	3284/US

METHOD OF PAYMENT		FEE CALCULATION (continued)	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to: Deposit Account Number 19-1025 Deposit Account Name <input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17 <input type="checkbox"/> Applicant claims small entity status. See 37 CFR § 1.27		3. ADDITIONAL FEES	
2. <input type="checkbox"/> Payment Enclosed: <input type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity Small Entity Fee Fee Fee Fee Code (\$) Code (\$) Fee Description Fee Paid		Large Entity Small Entity Fee Fee Fee Fee Code (\$) Code (\$) Fee Description Fee Paid	
101 710 201 355 Utility filing fee		105 130 205 65 Surcharge - late filing fee or oath	
106 320 206 160 Design filing fee		127 50 227 25 Surcharge - late provisional filing fee or cover sheet	
107 490 207 245 Plant filing fee		139 130 139 130 Non - English specification	
108 710 208 355 Reissue filing fee		147 2,520 147 2,520 For filing a request for <i>ex parte</i> reexamination	
114 150 214 75 Provisional filing fee		112 920* 112 920* Requesting publication of SIR prior to Examiner action	
SUBTOTAL (1)		113 1,840* 113 1,840* Requesting publication of SIR after Examiner action	
2. EXTRA CLAIM FEES		115 110 215 55 Extension for reply within first month	
Total Claims -20** = 0 X = 0.00		116 390 216 195 Extension for reply within second month	
Independent Claims -3** = 0 X = 0.00		117 890 217 445 Extension for reply within third month	
Multiple Dependent		118 1,390 218 695 Extension for reply within fourth month	
Large Entity Small Entity Fee Fee Fee Fee Code (\$) Code (\$) Fee Description Fee Paid		128 1,890 228 945 Extension for reply within fifth month	
103 18 203 9 Claims in excess of 20		119 310 219 155 Notice of Appeal	
102 80 202 40 Independent claims in excess of 3		120 310 220 155 Filing a brief in support of an appeal	
104 270 204 135 Multiple dependent claim, if not paid		121 270 221 135 Request for oral hearing	
109 80 209 40 ** Reissue independent claims over original patent		138 1,510 138 1,510 Petition to institute a public use proceeding	
110 18 210 9 ** Reissue claims in excess of 20 and over original patent		140 110 240 55 Petition to revive - unavoidable	
SUBTOTAL (2) \$0.00		141 1,240 241 620 Petition to revive - unintentional	
**or number previously paid, if greater; For Reissues, see above		142 1,240 242 620 Utility issue fee (or reissue)	
		143 440 243 220 Design issue fee	
		144 600 244 300 Plant issue fee	
		122 130 122 130 Petitions to the Commissioner	
		123 50 123 50 Processing fee under 37 CFR § 1.17(q)	
		126 180 126 180 Submission of Information Disclosure Statement 180.00	
		581 40 581 40 Recording each patent assignment per property (times number of properties)	
		146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))	
		149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))	
		179 710 279 355 Request for Continued Examination (RCE)	
		169 900 169 900 Request for expedited examination of a design application	
		Other fee (specify)	
		SUBTOTAL (3) \$180.00	
		*Reduced by Basic Filing Fee Paid	

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Rachel A. Polster	Registration No. (Attorney/Agent)	47,004
Signature	<i>Rachel A. Polster</i>	Telephone	636-737-5761
		Date	11/12/2001

WARNING: Information on this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC, 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Case C-3284/US

UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF)
)
 Khanna et al.) GROUP ART UNIT: Unknown
)
 SERIAL NO: 09/882,186) EXAMINER: Unknown
)
 FILED: June 15, 2001)
) DATE: November 12, 2001

TITLE: Cycloalkyl Alkanoic Acids as Integrin Receptor Antagonists

I hereby certify that this correspondence is being deposited with the
 United States Postal Service as first class mail in an envelope addressed to:
 Commissioner of Patents and Trademarks,
 Washington D.C., 20231 on November 26, 2001

Rachel A. Polster

Registration No. 47,004

Rachel A. Polster Date: *Nov. 26, 2001*

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.99

Hon. Commissioner of Patents & Trademarks
 Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR §1.97-1.99, as supplemented by MPEP §609. Attached is PTO Form 1449 listing documents believed to be material to the subject matter claimed in the above-identified application as of the filing date of said application.

Presentation of these documents listed on PTO Form-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37CFR §1.131 or otherwise.

The following patents and publications are listed on PTO Form-1449.

5,741,796	MERCK & CO.	04/21/98
WO 01/14337	MERCK & CO.	03/01/01
WO 01/14338	MERCK & CO.	03/01/01
WO 99/45927	SMITHKLINE	09/16/99
WO 00/38786	G.D. SEARLE & CO.	07/06/00
WO 00/38719	G.D. SEARLE & CO.	07/06/00
WO 00/38715	G.D. SEARLE & CO.	07/06/00
WO 00/38665	G.D. SEARLE & CO.	07/06/00
WO 00/64888	AVENTIS PHARMA.	11/02/00
WO 98/31359	MERCK & CO.	07/23/98
WO 98/20871	NIPPON CHEMIPHAR	05/22/98
WO 96/41795	FUJISAWA PHARMA	12/27/96
WO 95/32710	MERCK & CO.	12/07/95
WO 97/12878	BASF	04/10/97
EP 0 671 392	HOECHST AG	02/21/01
EP 0 478 328	MERCK & CO	01/10/96
WO 93/21166	SMITHKLINE BEECHAM	10/28/93
GB 2 264 115	BRITISH BIO-TECH	08/18/93
JP 10287634	OTSUKA PHARM.	10/27/98

Please charge the appropriate fee to Deposit Account
No. 19-1025.

Respectfully submitted



Rachel A. Polster
Registration No. 47,004
636-737-5761 (St. Louis)
fax 636-737-5452

Pharmacia Corporate Patent Department
800 N. Lindbergh Blvd.
Mail Zone 04E
St. Louis, MO 63167